How small business owners can avoid penalties for unpaid federal payroll taxes

dnrt8765

TAX GUY



a sign on the side of a building: Small business owners can find themselves owing penalties to the IRS if they fail to pay payroll taxes. Here’s how to avoid that. (Photo by ERIC BARADAT/AFP via Getty Images)


© ERIC BARADAT/AFP via Getty Images
Small business owners can find themselves owing penalties to the IRS if they fail to pay payroll taxes. Here’s how to avoid that. (Photo by ERIC BARADAT/AFP via Getty Images)

The federal government considers some tax sins to be much worse than others. One egregious sin is failing to pay over federal income and employment taxes that have been withheld from employee paychecks. In the COVID-19 era, that can happen to a cash-strapped business. If it does, the IRS can assess the so-called 100% penalty against any responsible person.

Loading...

Load Error

The

What We Learned About First Financial Northwest’s (NASDAQ:FFNW) CEO Compensation

dnrt8765

This article will reflect on the compensation paid to Joe Kiley who has served as CEO of First Financial Northwest, Inc. (NASDAQ:FFNW) since 2013. This analysis will also assess whether First Financial Northwest pays its CEO appropriately, considering recent earnings growth and total shareholder returns.

See our latest analysis for First Financial Northwest

How Does Total Compensation For Joe Kiley Compare With Other Companies In The Industry?

Our data indicates that First Financial Northwest, Inc. has a market capitalization of US$91m, and total annual CEO compensation was reported as US$674k for the year to December 2019. That’s mostly

Biohaven Reports Second Quarter 2020 Financial Results And Recent Business Developments

dnrt8765

– NURTEC™ ODT (rimegepant) achieved net revenues of $9.7M for the second quarter of 2020 and now NBRx market leader with 52.6% of share

– Company well-capitalized with recent non-dilutive financing of up to $950M from Sixth Street term loan and Royalty Pharma funding agreement

– Remains on timelines for NURTEC ODT sNDA filing for prevention of migraine in the coming months; additionally, completion of troriluzole Alzheimer’s Disease Phase 2/3 trial in 4Q2020, and topline results with troriluzole in Alzheimer’s Disease and Spinocerebellar Ataxia, and verdiperstat in Multiple System Atrophy in 2021

NEW HAVEN, Conn., Aug. 10, 2020 /PRNewswire/

Stoke Therapeutics Reports Second Quarter Financial Results and Provides Business Updates

dnrt8765

– First patient dosed with STK-001 in Part A of Phase 1/2a MONARCH clinical trial for Dravet syndrome –

– Company on track to identify an additional pre-clinical candidate derived from its TANGO platform for the treatment of an additional genetic disease in 2H 2020 –

– As of June 30, 2020, company has $202.1 million in cash, cash equivalents and restricted cash, anticipated to fund operations into 2023 –

Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company pioneering a new way to treat the underlying cause of genetic diseases by precisely upregulating protein expression, today reported financial results for